Clinical trial of tocilizumab for skin fibrosis in systemic sclerosis - Clinical trial of tocilizumab for skin fibrosis in systemic sclerosis

Yoshizaki Ayumi0 个研究点目标入组 5 人开始时间: 2019年3月18日最近更新: 2023年10月17日

适应症

试验速览

This study suggested that tocilizumab may improve skin sclerosis in systemic sclerosis safely.

•1)Patients with systemic sclerosis with sever skin sclerosis
•2)Over 6 modified Rodnan total skin score with skin sclerosis on fingers, dorsal hands, forearms, and upper arms; change of total skin score is within 20% during the screening period (two months)
•3)no malignancy
•4)from 20 years old to 80 years old
•5)Agreement to contraception during the study period
•6)Patients who are able to give consent in writing after reading the explanatory text

•1)during treatment with equal drug
•2)previous history of anaphylactic reactions to this drug
•3)significant infection
•4)significant liver damage
•5)significant renal damage
•6)pregnancy
•7)breast-feeding
•8)participating in other clinical trial within three months before the beginning of this trial
•9)judged inappropriate for this study by the physicians

发起方

Yoshizaki Ayumi